Related Experiment Video
Updated: Mar 22, 2026

09:59
A Magnetic Resonance Imaging Protocol for Stroke Onset Time Estimation in Permanent Cerebral Ischemia
Published on: September 16, 2017
14.7K
Quiet T1-Weighted Pointwise Encoding Time Reduction with Radial Acquisition for Assessing Myelination in the
1From the Department of Radiology (N.A., T.N., Y.F., K.N., M.E.), Kanagawa Children's Medical Center, Yokohama, Japan.
AJNR. American Journal of Neuroradiology
|April 9, 2016
Summary
Pointwise Encoding Time Reduction with Radial Acquisition (PETRA) sequences offer superior pediatric brain imaging quality and significantly reduced acoustic noise compared to MPRAGE. PETRA is a viable alternative for pediatric neuroimaging.
Area of Science:
- Radiology
- Neuroimaging
- Pediatric Imaging
Background:
- T1-weighted pointwise encoding time reduction with radial acquisition (PETRA) sequences are known for low gradient activity and quiet scanning.
- Assessing novel imaging techniques in pediatric populations is crucial for optimizing diagnostic procedures.
Purpose of the Study:
- To evaluate the utility of PETRA sequences in pediatric brain imaging.
- To compare PETRA with the established MPRAGE sequence in terms of image quality and acoustic noise.
Main Methods:
- A cohort of pediatric patients underwent both MPRAGE and PETRA brain MRI scans.
- Image quality was assessed by comparing contrast-to-noise and contrast ratios between white matter (WM) and gray matter (GM).
- Myelination was rated, and acoustic noise levels were measured for both sequences.
Main Results:
- PETRA demonstrated significantly higher contrast-to-noise and contrast ratios than MPRAGE (p < .05), except for cerebellar WM.
- Excellent intra- and interrater agreement were achieved for myelination assessment, with PETRA producing substantially lower acoustic noise (58.2 dB[A]) than MPRAGE (87.4 dB[A]).
Conclusions:
- PETRA provides superior objective image quality and significantly reduced acoustic noise compared to MPRAGE in pediatric brain imaging.
- PETRA is a suitable and potentially advantageous substitute for MPRAGE in this patient group.

